- May 6, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Synonyms :
Class :
may enhance the risk of adverse effects when combined with clobetasol propionate
may increase the risk or severity of adverse effects when combined
may increase the risk or severity of adverse effects when combined
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
it increases the adverse effects caused due to eptinezumab
It may enhance the immunosuppressive effects when combined with idecabtagene vicleucel
when both drugs are combined, there may be an increased metabolism of etoposide
when both drugs are combined, there may be an increased metabolism of vincristine
when both drugs are combined, the metabolism of paclitaxel increases
When both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
in combination with ofatumumab, adalimumab increases the risk of adverse events
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
interaction raises immunosuppressive effects and risk of infection
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk and severity of life-threatening infections
when both drugs are combined, there may be an increased risk or severity of adverse effects
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of abatacept
may increase the immunosuppressive effect of certolizumab pegol
may decrease the therapeutic effect of anticholinergic agents
may have an increased immunosuppressive effect when combined with anifrolumab
may have an increased immunosuppressive effect when combined with anti-psoriasis agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
it may enhance the adverse effects when combined with aducanumab
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
it may enhance the risk of side effects when combined with mitomycin
ximelagatran (investigational)
The combination of adalimumab may lead to an enhanced metabolism of ximelagatran
Combining methysergide and adalimumab can enhance methysergide's metabolism
Combining levobetaxolol and adalimumab can enhance levobetaxolol’s metabolism
When combined with adalimumab, levobupivacaine's metabolism can be enhanced
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
it may decrease the levels of serum concentration of Fosfomycin
it may decrease the levels of serum concentration of Sirolimus
tumor necrosis factor (TNF) blocking agent may enhance the immunosuppressive effect of anakinra
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
hydrocodone/chlorpheniramine/pseudoephedrine
may diminish the therapeutic effect
may diminish the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effects of opioid agonists
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of opioid agonists
may increase the risk or severity of toxic effects when combined
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of anticholinergic agents
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Opioid Agonists
buprenorphine,long-acting injection
may decrease the therapeutic effect of Opioid Agonists
Gastrointestinal agents may lower the serum levels of the antibiotic fosfomycin
acetaminophen/doxylamine/dextromethorphan
may decrease the therapeutic effect of anticholinergic Agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
decreases renal elimination of trimetrexate may lead to renal toxicity
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
